The world’s leading brand of fashionable colored masks officially launches on Amazon on August 8th from CSD, a professional disposable medical supplies manufacturer in Taiwan
TAIPEI, Aug. 8, 2022 /PRNewswire/ -- People dress according to mood, occasion, and necessity - and the mask, which inherently occupies half of the face, is an indispensable fashion accessory. On August 8th, COLO, a fashionable mask brand with colorful designs, will debut on Amazon in the United States, introducing two different series of masks that allow people to...
Xinhua Silk Road: E. China’s Wuxi city steps up biomedical industry development
BEIJING, Aug. 8, 2022 /PRNewswire/ -- The 2022 Taihu Bay Future Healthcare Conference held Thursday in Wuxi City in east China's Jiangsu Province witnessed the launch of Wuxi Intellectual Property Protection Center with 52 biomedical projects contracted, involving a total of more than 30 billion yuan investment. Photo shows 2022 Taihu Bay Future Healthcare Conference site Biomedical industry...
Qmed Asia launches Qmed GO “Mini Clinics” to Solve Rising Employee Healthcare Costs
Disrupting the medical landscape through an innovative internet-enabled clinical kiosk. KUALA LUMPUR, Malaysia, Aug. 8, 2022 /PRNewswire/ -- Qmed Asia launched the Qmed GO at the recent Malaysia International Retail and Franchise (MIRF) Exhibition 2022 held at the Kuala Lumpur Convention Centre in a bid to tackle corporate concerns on employee well-being, medical...
BIO Asia-Taiwan 2022 concludes, marking another successful edition of the region’s biggest bioindustry-focused conference and exhibition
Exhibition visitors surpass 100,000 people over 4 days BIO Asia–Taiwan success a testament to Taiwan's booming biotechnology industry TAIPEI, Aug. 8, 2022 /PRNewswire/ -- BIO Asia–Taiwan 2022, held at the TaiNEX 2 Exhibition Center, Nangang, Taipei, from 27-31 July, came to a successful conclusion on Sunday, 31st of July. Held in an innovative onsite-online format to encourage international participation,...
BioDuro-Sundia and X-Chem enter partnership to launch DEL services in China for the discovery of new small molecule drugs
SHANGHAI, Aug. 8, 2022 /PRNewswire/ -- BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library (DEL) technology services in China to help more innovative pharmaceutical companies quickly discover small molecule drugs. X-Chem will leverage its...
ImmVira’s Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA’s Orphan Drug Designation
SHENZHEN, China, Aug. 8, 2022 /PRNewswire/ -- On August 1, 2022, U.S. time, ImmVira's brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has obtained Orphan Drug Designation ("ODD") from U.S. Food and Drug Administration ("FDA"). Malignant glioma has been a special challenge for patients and healthcare professionals for a long time, with limited...
Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors
--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significant antitumor efficacy in preclinical studies as a single agent in multiple animal models --ASC61-A treatment induced secretion of IFNγ in a concentration dependent manner with an EC50 of 2.86 nM. Maximal levels of IFNγ induced by ASC61-A were similar to that induced by...
CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022
GEMSTONE-301 study result was presented at IASLC 2022 World Conference on Lung Cancer. In addition, the leading Principal Investigator Professor Yi-Long Wu was invited to highlight key data in a press conference In the final progression-free survival analysis, sugemalimab showed sustained clinical benefits in patients with unresectable stage III non-small cell lung cancer whose disease had not progressed...
Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema
SAN FRANCISCO and SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first patient with diabetic macular edema (DME) has been successfully dosed in the Phase 1 study of...
Transcenta Announces the Appointment of Dr. Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer
SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the appointment of Dr. Caroline Germa as the company's Executive Vice President, Global Medicine Development and Chief Medical Officer, reporting to Dr. Xueming Qian, CEO. Dr. Germa will...
